Characterization of the changes in eicosanoid profiles of activated macrophages treated with 20(S)-ginsenoside Rg3

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1065-1066, Issue , 2017, Pages 14-19

  Lee, Jae Won ^a   Choi, Yu Ri ^b   Mok, Hyuck Jun ^b   Seong, Hyun A ^c   Lee, Dae Young ^a   Kim, Geum Soog ^a   Yoon, Ji Hye ^a   Kim, Kwang Pyo ^b   Kim, Hyung Don ^a,c  

^a Rural Development Administration   (South Korea)

^b Kyung Hee University   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

Eicosanoid; Inflammation; Lipopolysaccharide; Macrophage; Rg3

Indexed keywords

CLUSTER ANALYSIS; HIERARCHICAL SYSTEMS; LIQUID CHROMATOGRAPHY; MACROPHAGES; MASS SPECTROMETRY; NITRIC OXIDE; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS;

ANTI-INFLAMMATORY ACTIVITY; EICOSANOID; HIERARCHICAL CLUSTER ANALYSIS; INFLAMMATION; LIPOPOLYSACCHARIDES; MULTIPLE REACTION MONITORING; TUMOR NECROSIS FACTOR ALPHA; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ENDOTHELIAL CELLS;

11 HYDROXYICOSATETRAENOIC ACID; 13 HYDROXY DOCOSAHEXAENOIC ACID; 9 HYDROXYICOSATETRAENOIC ACID; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; GINSENOSIDE RG 3; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOXIN B; NITRIC OXIDE; OXYLIPIN; PROSTAGLANDIN A2; PROSTAGLANDIN B2; PROSTAGLANDIN D; PROSTAGLANDIN D1; PROSTAGLANDIN D2; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN J2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; GINSENOSIDE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ICOSANOID METABOLISM; INFLAMMATION; MACROPHAGE ACTIVATION; MOUSE; MULTIPLE REACTION MONITORING; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RAW 264.7 CELL LINE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION; ANIMAL; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MACROPHAGE; METABOLISM;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; EICOSANOIDS; GINSENOSIDES; INFLAMMATION; MACROPHAGES; MICE; RAW 264.7 CELLS; TANDEM MASS SPECTROMETRY;

EID: 85029531166     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2017.09.002     Document Type: Article

References (39)

1. Liu, W., Xu, S., Che, C.-T., Anti-proliferative effect of ginseng saponins on human prostate cancer cell line. Life Sci. 67 (2000), 1297–1306.
2. Xie, J.-T., Mehendale, S.R., Li, X., Quigg, R., Wang, X., Wang, C.-Z., Wu, J.A., Aung, H.H., Rue, P.A., Bell, G.I., Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochimica et Biophysica Acta (BBA)–Mol. Basis Dis. 1740 (2005), 319–325.
3. Choi, K.-t., Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng CA Meyer. Acta Pharmacol. Sin., 29, 2008, 1109.
4. Kim, C.-S., Jo, Y.-J., Park, S.-H., Kim, H.-J., Han, J.-Y., Hong, J.-T., Cheong, J.-H., Oh, K.-W., Anti-stress effects of ginsenoside Rg 3-standardized ginseng extract in restraint stressed animals. Biomol. Ther. 18 (2010), 219–225.
5. Hong, C.-E., Lyu, S.-Y., Anti-inflammatory and anti-oxidative effects of Korean red ginseng extract in human keratinocytes. Immune Netw. 11 (2011), 42–49.
6. Kim, H.J., Kim, P., Shin, C.Y., A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. J. Ginseng Res. 37 (2013), 8–29.
7. Liao, B., Newmark, H., Zhou, R., Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. Exp. Neurol. 173 (2002), 224–234.
8. Lee, H.J., Kim, S.R., Kim, J.C., Kang, C.M., Lee, Y.S., Jo, S.K., Kim, T.H., Jang, J.S., Nah, S.Y., Kim, S.H., In vivo radioprotective effect of Panax ginseng CA Meyer and identification of active ginsenosides. Phytother. Res. 20 (2006), 392–395.
9. Lee, H.U., Bae, E.A., Han, M.J., Kim, N.J., Kim, D.H., Hepatoprotective effect of ginsenoside Rb1 and compound K on tert-butyl hydroperoxide-induced liver injury. Liver Int. 25 (2005), 1069–1073.
10. Tm, X., Man-hua, C., Xin, Y., Lp, G., Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin. Med. J. 121 (2008), 1394–1397.
11. Kang, K.S., Yamabe, N., Kim, H.Y., Park, J.H., Yokozawa, T., Therapeutic potential of 20 (S)-ginsenoside Rg 3 against streptozotocin-induced diabetic renal damage in rats. Eur. J. Pharmacol. 591 (2008), 266–272.
12. Cho, Y.-S., Kim, C.H., Kim, H.N., Ha, T.-S., Ahn, H.Y., Ginsenoside Rg3 inhibits lipopolysaccharide–induced adhesion molecule expression in human umbilical vein endothelial cell and C57BL/6 mice. Pharmazie 69 (2014), 818–822.
13. Lee, B., Sur, B., Park, J., Kim, S.-H., Kwon, S., Yeom, M., Shim, I., Lee, H., Hahm, D.-H., Ginsenoside rg3 alleviates lipopolysaccharide-induced learning and memory impairments by anti-inflammatory activity in rats. Biomol. Ther. (Seoul) 21 (2013), 381–390.
14. Keum, Y.-S., Han, S.S., Chun, K.-S., Park, K.-K., Park, J.-H., Lee, S.K., Surh, Y.-J., Inhibitory effects of the ginsenoside Rg 3 on phorbol ester-induced cyclooxygenase-2 expression, NF-κB activation and tumor promotion. Mutat. Res. 523 (2003), 75–85.
15. Pickup, J.C., Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27 (2004), 813–823.
16. Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005), 1685–1695.
17. Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420 (2002), 860–867.
18. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., Fiebich, B.L., Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000), 383–421.
19. Celli, B.R., Locantore, N., Yates, J., Tal-Singer, R., Miller, B.E., Bakke, P., Calverley, P., Coxson, H., Crim, C., Edwards, L.D., Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 185 (2012), 1065–1072.
20. Muni, R.H., Kohly, R.P., Lee, E.Q., Manson, J.E., Semba, R.D., Schaumberg, D.A., Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmol. 131 (2013), 514–521.
21. Calder, P.C., Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot. Essent. Fatty Acids 75 (2006), 197–202.
22. Serhan, C.N., Chiang, N., Van Dyke, T.E., Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8 (2008), 349–361.
23. Serhan, C.N., Yacoubian, S., Yang, R., Anti-inflammatory and pro-resolving lipid mediators. Annu. Rev. Pathol., 3, 2008, 279.
24. Mori, T.A., Beilin, L.J., Omega-3 fatty acids and inflammation. Curr. Atheroscler. Rep. 6 (2004), 461–467.
25. Kita, Y., Takahashi, T., Uozumi, N., Shimizu, T., A multiplex quantitation method for eicosanoids and platelet-activating factor using column-switching reversed-phase liquid chromatography–tandem mass spectrometry. Anal. Biochem. 342 (2005), 134–143.
26. Deems, R., Buczynski, M.W., Bowers-Gentry, R., Harkewicz, R., Dennis, E.A., Detection and quantitation of eicosanoids via high performance liquid chromatography-electrospray ionization-mass spectrometry. Methods Enzymol. 432 (2007), 59–82.
27. Mesaros, C., Lee, S.H., Blair, I.A., Targeted quantitative analysis of eicosanoid lipids in biological samples using liquid chromatography–tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877 (2009), 2736–2745.
28. Mal, M., Koh, P.K., Cheah, P.Y., Chan, E.C.Y., Ultra-pressure liquid chromatography/tandem mass spectrometry targeted profiling of arachidonic acid and eicosanoids in human colorectal cancer, Rapid Commun. Mass Spectrom. 25 (2011), 755–764.
29. Wolfer, A.M., Gaudin, M., Taylor-Robinson, S.D., Holmes, E., Nicholson, J.K., Development and validation of a high-throughput ultrahigh-performance liquid chromatography–mass spectrometry approach for screening of oxylipins and their precursors. Anal. Chem. 87 (2015), 11721–11731.
30. Lee, J.W., Mok, H.J., Lee, D.-Y., Park, S.C., Ban, M.S., Choi, J., Park, C.G., Ahn, Y.-S., Kim, K.P., Kim, H.D., UPLC-MS/MS-based profiling of eicosanoids in RAW264.7 cells treated with lipopolysaccharide. Int. J. Mol. Sci., 17, 2016, 508.
31. Shin, Y.-M., Jung, H.-J., Choi, W.-Y., Lim, C.-J., Antioxidative, anti-inflammatory, and matrix metalloproteinase inhibitory activities of 20 (S)-ginsenoside Rg3 in cultured mammalian cell lines. Mol. Biol. Rep. 40 (2013), 269–279.
32. Park, J.-S., Park, E.-M., Kim, D.-H., Jung, K., Jung, J.-S., Lee, E.-J., Hyun, J.-W., Kang, J.L., Kim, H.-S., Anti-inflammatory mechanism of ginseng saponins in activated microglia. J. Neuroimmunol. 209 (2009), 40–49.
33. Kortz, L., Dorow, J., Ceglarek, U., Liquid chromatography–tandem mass spectrometry for the analysis of eicosanoids and related lipids in human biological matrices: a review. J. Chromatogr. B 964 (2014), 1–11.
34. Serhan, C.N., Hamberg, M., Samuelsson, B., Morris, J., Wishka, D.G., On the stereochemistry and biosynthesis of lipoxin B. Proc. Natl. Acad. Sci. U. S. A. 83 (1986), 1983–1987.
35. Serhan, C.N., Hamberg, M., Samuelsson, B., Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. U. S. A. 81 (1984), 5335–5339.
36. Elabdeen, H.R.Z., Mustafa, M., Szklenar, M., Rühl, R., Ali, R., Bolstad, A.I., Ratio of pro-resolving and pro-inflammatory lipid mediator precursors as potential markers for aggressive periodontitis. PLoS One, 8, 2013, e70838.
37. Le Faouder, P., Baillif, V., Spreadbury, I., Motta, J.-P., Rousset, P., Chêne, G., Guigné, C., Tercé, F., Vanner, S., Vergnolle, N., LC–MS/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 932 (2013), 123–133.
38. Norris, P.C., Dennis, E.A., A lipidomic perspective on inflammatory macrophage eicosanoid signaling. Adv. Biol. Regul. 54 (2014), 99–110.
39. Trebino, C.E., Eskra, J.D., Wachtmann, T.S., Perez, J.R., Carty, T.J., Audoly, L.P., Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. J. Biol. Chem. 280 (2005), 16579–16585.